ScoreWhy is Axsome Therapeutics, Inc. ?
1
With a growth in Net Sales of 14.21%, the company declared Very Positive results in Jun 26
- OPERATING CASH FLOW(Y) Highest at USD -71.25 MM
- NET PROFIT(HY) Higher at USD -116.76 MM
- RAW MATERIAL COST(Y) Fallen by -3.22% (YoY)
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 72.87%, its profits have risen by 32.4%
3
High Institutional Holdings at 93.5%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
- Their stake has increased by 7.25% over the previous quarter.
4
Market Beating Performance
- The stock has generated a return of 72.87% in the last 1 year, much higher than market (S&P 500) returns of 16.00%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Axsome Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Axsome Therapeutics, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Axsome Therapeutics, Inc.
63.68%
4.06
45.03%
S&P 500
15.76%
1.22
13.15%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
264.06%
EBIT Growth (5y)
-21.77%
EBIT to Interest (avg)
-26.97
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-2.20
Sales to Capital Employed (avg)
1.39
Tax Ratio
0.03%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
86.25%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
90.58
EV to EBIT
-46.48
EV to EBITDA
-49.07
EV to Capital Employed
-179.12
EV to Sales
12.32
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-198.50%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend14What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -71.25 MM
NET PROFIT(HY)
Higher at USD -116.76 MM
RAW MATERIAL COST(Y)
Fallen by -3.22% (YoY
NET SALES(Q)
Highest at USD 218.38 MM
-2What is not working for the Company
INVENTORY TURNOVER RATIO(HY)
Lowest at 2.22 times
Here's what is working for Axsome Therapeutics, Inc.
Operating Cash Flow
Highest at USD -71.25 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Profit
Higher at USD -116.76 MM
than preceding 12 month period ended Jun 2026MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Net Sales
Highest at USD 218.38 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Net Sales
At USD 218.38 MM has Grown at 23.33%
over average net sales of the previous four periods of USD 177.06 MMMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Raw Material Cost
Fallen by -3.22% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Depreciation
Highest at USD 2.89 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (USD MM)
Here's what is not working for Axsome Therapeutics, Inc.
Inventory Turnover Ratio
Lowest at 2.22 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
Footer loading
